Kao XM, Zhu X, Zhang JL, Chen SQ, Fan CG. FGFR2-TSC22D1, a novel FGFR2 fusion gene identified in a patient with colorectal cancer: A case report. World J Clin Cases 2021; 9(23): 6867-6871 [PMID: 34447836 DOI: 10.12998/wjcc.v9.i23.6867]
Corresponding Author of This Article
Chao-Gang Fan, PhD, Chief Doctor, Department of General Surgery, The Affiliated BenQ Hospital of Nanjing Medical University, No. 71 Hexi Street, Jianye District, Nanjing 210002, Jiangsu Province, China. fancg2002@hotmail.com
Research Domain of This Article
Immunology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Aug 16, 2021; 9(23): 6867-6871 Published online Aug 16, 2021. doi: 10.12998/wjcc.v9.i23.6867
FGFR2-TSC22D1, a novel FGFR2 fusion gene identified in a patient with colorectal cancer: A case report
Xiao-Ming Kao, Xi Zhu, Jun-Ling Zhang, Shi-Qing Chen, Chao-Gang Fan
Xiao-Ming Kao, Xi Zhu, Research Institure of General Surgery, Jinling Hospital, Nanjing 210002, Jiangsu Province, China
Jun-Ling Zhang, Shi-Qing Chen, Department of Medical, 3D Medicines Inc., Shanghai 201114, China
Chao-Gang Fan, Department of General Surgery, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing 210002, Jiangsu Province, China
Author contributions: Fan CG performed the conception and design of the study; Kao XM and Zhu X performed the acquisition of clinical data; Zhang JL and Chen SQ performed the analysis and interpretation of the data; Fan CG and Kao XM performed the manuscript drafting and revision; all authors performed the final approval of the manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: JZ and SC were employed by Shanghai 3D Medicines Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chao-Gang Fan, PhD, Chief Doctor, Department of General Surgery, The Affiliated BenQ Hospital of Nanjing Medical University, No. 71 Hexi Street, Jianye District, Nanjing 210002, Jiangsu Province, China. fancg2002@hotmail.com
Received: March 17, 2021 Peer-review started: March 17, 2021 First decision: April 4, 2021 Revised: April 13, 2021 Accepted: June 28, 2021 Article in press: June 28, 2021 Published online: August 16, 2021 Processing time: 141 Days and 5.2 Hours
Abstract
BACKGROUND
The FGFR signaling pathway is activated in multiple tumor types through gene amplifications, single base substitutions, or gene fusions. Novel FGFR gene fusions may represent candidate targets for the development of tyrosine kinase inhibitors.
CASE SUMMARY
Herein, we report a patient with colorectal cancer (CRC) harboring a novel FGFR2 fusion gene. A 59-year-old man felt discomfort in his right upper abdomen with loss of appetite for 6 mo. An abdominal computed tomography scan revealed the existence of a space-occupying lesion in the ascending colon. The pathological diagnosis was a poorly differentiated adenocarcinoma. Subsequent biopsy specimen was subjected to next-generation sequencing analysis, and a novel FGFR2-TSC22D1 fusion with complete kinase structure of FGFR2 protein was identified.
CONCLUSION
We report the first case of CRC harboring FGFR2-TSC22D1, which enriches the FGFR2 fusion spectrum. FGFR2 inhibitors might be effective in the later treatment for this patient.
Core Tip: A colorectal cancer patient had a novel FGFR2-TSC22D1 fusion which included exons 1-17 of FGFR2 and exons 3 of TSC22D1. This fusion contains FGFR2 kinase domain and coil coiled domains encoded by TSC22D1 exon 3, which might induce oncogenesis. Our case enriches the FGFR2 fusion spectrum. We believe that these novel findings have important implications in the strategy development of therapy for colorectal cancer.
